» Articles » PMID: 36964570

Negative Regulation of CD44st by MiR-138-5p Affects the Invasive Ability of Breast Cancer Cells and Patient Prognosis After Breast Cancer Surgery

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2023 Mar 25
PMID 36964570
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate how the negative regulation of CD44st by miR-138-5p affects the invasive ability of breast cancer cell lines and prognosis in postoperative breast cancer patients.

Methods: RT-PCR, qRT-PCR, and western blot assays were used to detect the expression of CD44s, CD44v6, and CD44st at both mRNA and protein levels. The expression of miR-138-5p in breast cancer cell lines was also evaluated. The binding ability of miR-138-5p to CD44st was determined via a dual-luciferase assay. The CD44 protein expression in breast cancer tissues was detected using immunohistochemistry. A Transwell assay was used to detect the invasive ability of tumor cells. The correlation between CD44st and miR-138-5p mRNA expression in breast cancer tissues was evaluated using qRT-PCR, and the relationship between clinicopathological features was statistically analyzed.

Results: CD44s and CD44v6 were highly expressed in MDAMB-231 cell line, while CD44st was highly expressed in MCF-7/Adr and Skbr-3 cells. None of the CD44 isoforms were expressed in MCF-7 cells. The miR-138-5p was highly expressed in MCF-7 cells, but not in MCF-7/Adr, Skbr-3, and MDAMB-231 cells. The dual-luciferase assay suggested that miR-138-5p could bind to wild-type CD44st 3'-UTR, miR-138-5p overexpression significantly inhibited the expression level of CD44 protein in MCF-7/Adr cells, and miR-138-5p + CD44st (3'-UTR)-treated MCF-7/Adr and Skbr-3 cells were significantly less invasive than those in the control group (P < 0.05). RT-PCR results for 80 postoperative breast cancer patients showed that the mRNA expression rate for CD44st was higher in cancer tissues than in paracancerous tissues, and the expression rate of miR-138-5p was higher in paracancerous tissues than in cancerous tissues (P < 0.01). In cancer tissues, CD44st was negatively correlated with miR-138-5p expression, with correlation coefficient r = -0.76 (Pearson's correlation), coefficient of determination R2 = 0.573, F = 106.89, and P < 0.001. The median overall survival value for patients in the low miR-138-5p expression group was 40.39 months [95% confidence interval (CI): 35.59-45.18 months] and 56.30 months (95% CI: 54.38-58.21 months) for patients in the high-expression group, with a log rank (Mantel-Cox) of 13.120, one degree of freedom, and P < 0.001.

Conclusion: In breast cancer cell lines, miR-138-5p negatively regulated expression of CD44st and affected the invasive ability of tumor cells and patient prognosis after breast cancer surgery.

Citing Articles

Identification and Validation of circDOCK1/miR-138-5p/GRB7 Axis for Promoting Breast Cancer Progression.

Zhang Y, Yang M, Wang Y, Zhao J, Lee P, Ma Y Breast Cancer (Dove Med Press). 2024; 16:795-810.

PMID: 39628959 PMC: 11611708. DOI: 10.2147/BCTT.S495517.

References
1.
Zuo J, Zhu K, Wang Y, Yu Z . MicroRNA-34a suppresses invasion and metastatic in esophageal squamous cell carcinoma by regulating CD44. Mol Cell Biochem. 2017; 443(1-2):139-149. DOI: 10.1007/s11010-017-3218-3. View

2.
Inoue K, Fry E . Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer. Genet Epigenet. 2015; 7:19-32. PMC: 4669075. DOI: 10.4137/GEG.S35500. View

3.
Liang Z, Feng Q, Xu L, Li S, Zhou L . CREPT regulated by miR-138 promotes breast cancer progression. Biochem Biophys Res Commun. 2017; 493(1):263-269. DOI: 10.1016/j.bbrc.2017.09.033. View

4.
Tokunaga E, Fujita A, Takizawa K, Baba K, Akiyoshi S, Nakamura Y . CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy. Breast Cancer. 2018; 26(1):47-57. PMC: 6314992. DOI: 10.1007/s12282-018-0888-y. View

5.
Fang Z, Li T, Chen W, Wu D, Qin Y, Liu M . Gab2 promotes cancer stem cell like properties and metastatic growth of ovarian cancer via downregulation of miR-200c. Exp Cell Res. 2019; 382(1):111462. DOI: 10.1016/j.yexcr.2019.06.007. View